CoChat
Sign Up
Cited by 9

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Bispecific fibrous glue synergistically boosts vascular normalization and antitumor immunity for advanced renal carcinoma therapy

Wu, Xiu-Hai, Wang, Jia-Qi, Wang, Man-Di, Xiao, Ting, Wang, Yu, Niu, Jia-Yuan, Wang, Lu, Hou, Da-Yong, Fu, Bo, Liu, Zimo, Wang, Hao, Xu, Wanhai·2024·Biomaterials
DOI 10.1016/j.biomaterials.2024.122550
Open this paper in CoChat — free account

Abstract

Immune checkpoint blockade therapy represented by programmed cell death ligand 1 (PD-L1) inhibitor for advanced renal carcinoma with an objective response rate (ORR) in patients is less than 20%. It is attributed to abundant tumoral vasculature with abnormal structure limiting effector T cell infiltration and drug penetration. We propose a bispecific fibrous glue (BFG) to regulate tumor immune and vascular microenvironments simultaneously. The bispecific precursor glue peptide-1 (pre-GP1) can penetrate tumor tissue deeply and self-assemble into BFG in the presence of neuropilin-1 (NRP-1) and PD-L1. The resultant fibrous glue is capable of normalizing tumoral vasculature as well as restricting immune escape. The pre-GP1 retains a 6-fold higher penetration depth than that of antibody in the multicellular spheroids (MCSs) model. It also shows remarkable tumor growth inhibition (TGI) from 19% to 61% in a murine advanced large tumor model compared to the clinical combination therapy. In addition, in the orthotopic renal tumor preclinical model, the lung metastatic nodules are reduced by 64% compared to the clinically used combination. This pre-GP1 provides a promising strategy to control the progression and metastasis of advanced renal carcinoma.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.biomaterials.2024.122550

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 4 references

Research works printed but not linked: 45

  1. Bedke, 2023, The 2022 updated European association of urology guidelines on the use of adjuvant immune checkpoint inhibitor therapy for renal cell carcinoma, Eur. Urol., 83, 10, 10.1016/j.eururo.2022.10.010 · DOI
  2. Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA A Cancer J. Clin., 71, 209, 10.3322/caac.21660 · DOI · Paper page
  3. Atkins, 2018, Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma, Cancer Treat Rev., 70, 127, 10.1016/j.ctrv.2018.07.009 · DOI
  4. Bedke, 2018, Immunotherapy for kidney cancer: status quo and the future, Curr. Opin. Urol., 28, 8, 10.1097/MOU.0000000000000466 · DOI
  5. Patel, 2020, Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery, Curr. Opin. Oncol., 32, 240, 10.1097/CCO.0000000000000621 · DOI
  6. Guarch, 2018, High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma, Ann. Diagn. Pathol., 34, 27, 10.1016/j.anndiagpath.2018.01.001 · DOI
  7. McDermott, 2016, Atezolizumab, an anti-programmed death-ligand 1 antibody, Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34, 833
  8. Fukumura, 2018, Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges, Nat. Rev. Clin. Oncol., 15, 325, 10.1038/nrclinonc.2018.29 · DOI · Paper page
  9. Jain, 2005, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science (New York, N.Y.), 307, 58, 10.1126/science.1104819 · DOI · Paper page
  10. Munn, 2019, Vascular regulation of antitumor immunity, Science (New York, N.Y.), 365, 544, 10.1126/science.aaw7875 · DOI
  11. Mortezaee, 2021, Normalization in tumor ecosystem: opportunities and challenges, Cell Biol. Int., 45, 10.1002/cbin.11655 · DOI
  12. Tegos, 2019, Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma, Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 24, 1340
  13. Rini, 2019, Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial, Lancet (London, England), 393, 2404, 10.1016/S0140-6736(19)30723-8 · DOI
  14. Motzer, 2019, Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N. Engl. J. Med., 380, 1103, 10.1056/NEJMoa1816047 · DOI
  15. Parmar, 2020, Systemic therapy in metastatic renal cell carcinoma: emerging challenges in therapeutic choice, Crit. Rev. Oncol.-Hematol., 152, 10.1016/j.critrevonc.2020.102971 · DOI
  16. Hutson, 2016, The evolution of systemic therapy in metastatic renal cell carcinoma, American society of clinical oncology educational book, American Society of Clinical Oncology. Annual Meeting, 35, 113
  17. Goodman, 2017, Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers, Mol. Cancer Therapeut., 16, 2598, 10.1158/1535-7163.MCT-17-0386 · DOI · Paper page
  18. Chowdhury, 2021, A phase I/II study to assess the safety and efficacy of pazopanib and pembrolizumab combination therapy in patients with advanced renal cell carcinoma, Clin. Genitourin. Cancer, 19, 434, 10.1016/j.clgc.2021.04.007 · DOI
  19. Tian, 2022, Acute kidney injury induced by immune checkpoint inhibitors, Kidney Dis., 8, 190, 10.1159/000520798 · DOI
  20. Hu, 2023, An in vivo self-assembled bispecific nanoblocker for enhancing tumor immunotherapy, Adv. Mater., 35, 10.1002/adma.202303831 · DOI
  21. An, 2023, A bispecific glycopeptide spatiotemporally regulates tumor microenvironment for inhibiting bladder cancer recurrence, Sci. Adv., 9, eabq8225, 10.1126/sciadv.abq8225 · DOI
  22. Lu, 2019, The functions and applications of A7R in anti-angiogenic therapy, imaging and drug delivery systems, Asian J. Pharm. Sci., 14, 595, 10.1016/j.ajps.2019.04.004 · DOI
  23. Nguyen, 2023, Mechanisms of ADC toxicity and strategies to increase ADC tolerability, Cancers, 15, 10.3390/cancers15030713 · DOI · Paper page
  24. Kuusk, 2017, Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer, Angiogenesis, 20, 205, 10.1007/s10456-017-9550-0 · DOI
  25. Xiao, 2015, Peptide-based treatment: a promising cancer therapy, Journal of immunology research, 2015, 10.1155/2015/761820 · DOI
  26. Chang, 2016, CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells, Cancer Res., 76, 5671, 10.1158/0008-5472.CAN-16-0144 · DOI · Paper page
  27. Winkler, 2004, Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases, Cancer Cell, 6, 553
  28. Zheng, 2021, Targeting tumor vascularization: promising strategies for vascular normalization, J. Cancer Res. Clin. Oncol., 147, 2489, 10.1007/s00432-021-03701-8 · DOI
  29. Singh, 2020, Antibody coadministration as a strategy to overcome binding-site barrier for ADCs: a quantitative investigation, AAPS J., 22, 28, 10.1208/s12248-019-0387-x · DOI
  30. Abbott, 2019, Cancer and the immune system: the history and background of immunotherapy, Semin. Oncol. Nurs., 35, 10.1016/j.soncn.2019.08.002 · DOI
  31. Wang, 2020, Transformable dual-inhibition system effectively suppresses renal cancer metastasis through blocking endothelial cells and cancer stem cells, Small, 16
  32. Wang-Bishop, 2023, STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy, Science immunology, 8, 10.1126/sciimmunol.add1153 · DOI
  33. Powles, 2020, Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial, Lancet Oncol., 21, 1563, 10.1016/S1470-2045(20)30436-8 · DOI · Paper page
  34. Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N. Engl. J. Med., 356, 115, 10.1056/NEJMoa065044 · DOI
  35. Abdelgalil, 2019, vol. 44, 239
  36. Viallard, 2017, Tumor angiogenesis and vascular normalization: alternative therapeutic targets, Angiogenesis, 20, 409, 10.1007/s10456-017-9562-9 · DOI
  37. Mac Gabhann, 2006, Targeting neuropilin-1 to inhibit VEGF signaling in cancer: comparison of therapeutic approaches, PLoS Comput. Biol., 2
  38. Rad-Malekshahi, 2016, Biomedical applications of self-assembling peptides, Bioconjugate Chem., 27, 3, 10.1021/acs.bioconjchem.5b00487 · DOI
  39. Hou, 2024, In vivo assembly enhanced binding effect augments tumor specific ferroptosis therapy, Nat. Commun., 15, 454, 10.1038/s41467-023-44665-2 · DOI
  40. Hou, 2022, OGA activated glycopeptide-based nano-activator to activate PKM2 tetramerization for switching catabolic pathways and sensitizing chemotherapy resistance, Biomaterials, 284, 10.1016/j.biomaterials.2022.121523 · DOI
  41. Hou, 2022, In situ constructed nano-drug depots through intracellular hydrolytic condensation for chemotherapy of bladder cancer, Angew. Chem., 61, 10.1002/anie.202116893 · DOI
  42. Hou, 2024, Inducing mitochondriopathy-like damages by transformable nucleopeptide nanoparticles for targeted therapy of bladder cancer, Natl. Sci. Rev., 11, 10.1093/nsr/nwae028 · DOI
  43. Vafaei, 2022, Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier, Cancer Cell Int., 22, 2, 10.1186/s12935-021-02407-8 · DOI
  44. Kumar, 2017, Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy, Front. Pharmacol., 8, 49, 10.3389/fphar.2017.00049 · DOI
  45. Sadik, 2020, Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six German dermatology centers, Front. Immunol., 11

Cited by

Sorted by citations

Metadata

Authors
Wu, X.-H., Wang, J.-Q., Wang, M.-D., Xiao, T., Wang, Y., Niu, J.-Y., Wang, L., Hou, D.-Y., Fu, B., Liu, Z., Wang, H., & Xu, W.
Venue
Biomaterials
Publisher
Elsevier BV
Published
2024-07
Volume
308
Pages
122550
ISSN
0142-9612
DOI
10.1016/j.biomaterials.2024.122550
Cited by
9
References
4
Language
en
Licence
Funders
  • National Key Research and Development Program of China (2021YFB3801004)
  • Key Research and Development Program of Heilongjiang (2022ZX06004)
  • National Natural Science Foundation of China (52273216, 2022YFA1205701, 52003270, 51725302, U20A20385)
  • National Key Research and Development Program of China Stem Cell and Translational Research (2021YFB3801000)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review